FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212812892> ?p ?o ?g. }

• W3212812892 endingPage "449" @default.
• W3212812892 startingPage "449" @default.
• W3212812892 abstract "Abstract Introduction: Most patients diagnosed with diffuse large B cell lymphoma (DLBCL) are cured with combination chemoimmunotherapy, but 40% will develop relapsed or refractory (r/r) disease, which is often associated with a poor clinical outcome. PD-1 blockade therapy has been investigated in r/r DLBCL; however, response rates in unselected DLBCL patients are disappointing, highlighting the need for deeper understanding of DLBCL immune landscapes, as well as mechanisms that regulate the immune response to checkpoint blockade therapy (CBT) in this disease. In solid cancers, tumor-cell intrinsic oncogenic signaling strongly influences the immune environment and impacts clinical response to CBT. Despite the recent publication of large-scale genomic datasets in DLBCL, the impact of oncogenic signaling on the immune environment remains to be fully elucidated. In this study, we aimed to characterize immune landscapes associated with DLBCL, as well as the role of lymphoma-intrinsic alterations on shaping the immune environment in this disease. Methods: Using gene set variation analysis (GSVA) in a large cohort of primary DLBCLs (n = ~900), a sample-wise enrichment score was generated for gene sets associated with tumor infiltrating lymphocytes. Gene sets were manually curated to include signatures relating to IFNγ response, T helper cell subsets, CD8 + T cell exhaustion, macrophages, and dendritic cells. A DLBCL cell-of-origin (COO) signature was also included in the GSVA to control for the transcriptional and genomic effects of COO. Samples were hierarchically clustered into related groups. Multispectral immunofluorescence (mIF) for canonical T cell markers was used to confirm GSVA clustering. To mechanistically validate our findings, CRISPR/Cas9 gene editing was used to modulate candidate oncogenes and tumor suppressors genes (TSGs) in the syngeneic A20 murine lymphoma model. Results: GSVA performed on transcriptomes from a large genomic DLBCL dataset revealed four distinct DLBCL immune clusters, termed ABC hot, ABC cold, GCB hot and GCB cold, defined by differential expression scores of immune related gene sets (Fig 1A). Concordant with our previous work, DLBCLs with PD-L1 gene amplifications, which are associated with a T-cell inflamed tumor microenvironment, were enriched in the ABC hot cluster (Fig 1B). Conversely, double hit signature DLBCLs, known to be associated with decreased immune cell infiltration and a GCB COO, were enriched in GCB cold DLBCLs (Fig 1C). In an internal cohort of diagnostic DLBCL samples (n = 90) for whom RNA sequencing (RNAseq) and FFPE tissue were available, mIF analysis showed that both ABC hot and GCB hot DLBCLs had significantly higher ratios of CD8 + T cells to lymphoma cells compared to cold DLBCLs. ABC hot DLBCLs also had a significantly higher CD4 + T cell to lymphoma cell ratio (Fig 1D). Importantly, several mutations that correlated with particular DLBCL immune clusters were identified. The ABC cold cluster was significantly enriched for loss-of-function (LOF) mutations in TMEM30A and MYD88, whereas LOF mutations in ATM and FOXO1 were commonly observed in GCB cold DLBCLs. Finally, LOF mutations in SOCS1 and B2M were significantly enriched in GCB hot DLBCLs (Fig 1E, 1F). As LOF SOCS1 mutations were strongly associated with GCB hot DLBCLs and are also prevalent in other CBT-sensitive lymphomas, we hypothesized that SOCS1 LOF mutations would enhance lymphoma cell vulnerability to CBT due to increased IFNγ sensitivity resulting from unopposed JAK/STAT activation. To test this hypothesis, we generated Socs1 deficient A20 lymphoma cells. Compared to A20 WT, A20 Socs1-/- cells were characterized by increased pStat1 levels upon IFNγ stimulation (Fig 1G). Interestingly, A20 Socs1-/- tumors showed increased sensitivity to α-PD1 therapy compared to A20 WT in syngeneic hosts. Together, these data suggest that tumor-cell intrinsic JAK/STAT activation via SOCS1 -/- increases lymphoma cell sensitivity to IFNγ and α-PD1 therapy (Fig 1H). Conclusion: We have developed a novel immunogenomic platform to define the role of tumor-cell intrinsic alterations on the immune landscape of DLBCL. Confirmatory studies using in vitro and in vivo models validated the effect of key oncogenes and TSGs on the tumor microenvironment, and suggest these candidate genes may impact response to CBT in DLBCL. Figure 1 Figure 1. Disclosures Smith: Alexion, AstraZeneca Rare Disease: Other: Study investigator; Celgene, Genetech, AbbVie: Consultancy. Steidl: Trillium Therapeutics: Research Funding; Curis Inc.: Consultancy; Epizyme: Research Funding; Seattle Genetics: Consultancy; Bayer: Consultancy; AbbVie: Consultancy; Bristol-Myers Squibb: Research Funding. Kline: Seagen: Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Speakers Bureau; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Research Funding; Verastem: Research Funding; SecuraBio: Membership on an entity's Board of Directors or advisory committees; Regeneron: Membership on an entity's Board of Directors or advisory committees." @default.
• W3212812892 created "2021-11-22" @default.
• W3212812892 creator A5002727955 @default.
• W3212812892 creator A5005159945 @default.
• W3212812892 creator A5008824892 @default.
• W3212812892 creator A5015389834 @default.
• W3212812892 creator A5048030695 @default.
• W3212812892 creator A5077036385 @default.
• W3212812892 creator A5078862843 @default.
• W3212812892 creator A5080562599 @default.
• W3212812892 creator A5091240481 @default.
• W3212812892 date "2021-11-05" @default.
• W3212812892 modified "2023-09-28" @default.
• W3212812892 title "Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations" @default.
• W3212812892 doi "https://doi.org/10.1182/blood-2021-153724" @default.
• W3212812892 hasPublicationYear "2021" @default.
• W3212812892 type Work @default.
• W3212812892 sameAs 3212812892 @default.
• W3212812892 citedByCount "0" @default.
• W3212812892 crossrefType "journal-article" @default.
• W3212812892 hasAuthorship W3212812892A5002727955 @default.
• W3212812892 hasAuthorship W3212812892A5005159945 @default.
• W3212812892 hasAuthorship W3212812892A5008824892 @default.
• W3212812892 hasAuthorship W3212812892A5015389834 @default.
• W3212812892 hasAuthorship W3212812892A5048030695 @default.
• W3212812892 hasAuthorship W3212812892A5077036385 @default.
• W3212812892 hasAuthorship W3212812892A5078862843 @default.
• W3212812892 hasAuthorship W3212812892A5080562599 @default.
• W3212812892 hasAuthorship W3212812892A5091240481 @default.
• W3212812892 hasBestOaLocation W32128128921 @default.
• W3212812892 hasConcept C167672396 @default.
• W3212812892 hasConcept C203014093 @default.
• W3212812892 hasConcept C2776090121 @default.
• W3212812892 hasConcept C2777701055 @default.
• W3212812892 hasConcept C2778559949 @default.
• W3212812892 hasConcept C2779338263 @default.
• W3212812892 hasConcept C2779916150 @default.
• W3212812892 hasConcept C2780790343 @default.
• W3212812892 hasConcept C2780851360 @default.
• W3212812892 hasConcept C502942594 @default.
• W3212812892 hasConcept C86803240 @default.
• W3212812892 hasConcept C8891405 @default.
• W3212812892 hasConceptScore W3212812892C167672396 @default.
• W3212812892 hasConceptScore W3212812892C203014093 @default.
• W3212812892 hasConceptScore W3212812892C2776090121 @default.
• W3212812892 hasConceptScore W3212812892C2777701055 @default.
• W3212812892 hasConceptScore W3212812892C2778559949 @default.
• W3212812892 hasConceptScore W3212812892C2779338263 @default.
• W3212812892 hasConceptScore W3212812892C2779916150 @default.
• W3212812892 hasConceptScore W3212812892C2780790343 @default.
• W3212812892 hasConceptScore W3212812892C2780851360 @default.
• W3212812892 hasConceptScore W3212812892C502942594 @default.
• W3212812892 hasConceptScore W3212812892C86803240 @default.
• W3212812892 hasConceptScore W3212812892C8891405 @default.
• W3212812892 hasIssue "Supplement 1" @default.
• W3212812892 hasLocation W32128128921 @default.
• W3212812892 hasOpenAccess W3212812892 @default.
• W3212812892 hasPrimaryLocation W32128128921 @default.
• W3212812892 hasRelatedWork W1996150995 @default.
• W3212812892 hasRelatedWork W2023771859 @default.
• W3212812892 hasRelatedWork W3001665703 @default.
• W3212812892 hasRelatedWork W3039388108 @default.
• W3212812892 hasRelatedWork W3082396803 @default.
• W3212812892 hasRelatedWork W3174769180 @default.
• W3212812892 hasRelatedWork W3212812892 @default.
• W3212812892 hasRelatedWork W4210960713 @default.
• W3212812892 hasRelatedWork W4213233043 @default.
• W3212812892 hasRelatedWork W4378715746 @default.
• W3212812892 hasVolume "138" @default.
• W3212812892 isParatext "false" @default.
• W3212812892 isRetracted "false" @default.
• W3212812892 magId "3212812892" @default.
• W3212812892 workType "article" @default.